Hints and tips:
...Alicia García-Herrero, chief Asia-Pacific economist at Natixis, said Li’s failure to appear before the media would further dent investor confidence in China’s economy, following the tightening of access...
...Gary Ng, a senior economist at French bank Natixis, says that growing numbers of foreign investors find it more difficult to look at Hong Kong’s status separately from that of mainland China....
...Last week, Mr Gabay told the FT: “Merit Capital incorporated in Belgium has not traded with H2O.”...
...The strongest action we’ve seen so far has come from Natixis....
...Many enthusiasts for ML also love to conjure up scenarios where alternative data sources are incorporated....
...said it was continuing to push for a “pragmatic and timely solution” so that it could continue providing clearing services for its European members, which are banks ABN Amro, Commerzbank, Deutsche Bank, Natixis...
...Natixis gobbles up more M&A boutiques Natixis is on an M&A roll....
...“Frankly, I had expected Agendia to gain more market share,” said Dr Ashim Anand, who follows the medical diagnostics industry for Natixis Bleichroeder....
...Natixis Bleichroeder analysts said a deal could end the “game of mutually assured destruction” played by the two companies as they stepped further into each other’s core areas....
...IAC is trading at just 2 times next year’s expected earnings before interest, tax, depreciation and amortisation, according to Alan Gould, an analyst with Natixis Bleichroeder....
...John Roque, of Natixis Bleichroeder, points out that advancers heavily outnumbered decliners, but they could have done so by a greater margin....
...Jon LeCroy, analyst at Natixis Bleichroeder, said: “As a result of the delay to these trials, we are pushing out the expected launch of Prasugrel from 2008 to 2009.”...
...Jon LeCroy, analyst at Natixis Bleichroeder, says Pfizer’s strategy is evidence that “bigger is rarely better”....
International Edition